RxDoctor Payments Data

Cristina Lopez Beauchamp, MD

Glaucoma Specialist · San Juan, PRNPI 1720469190

Payments from drug & device makers

$1,646in general payments, 2019–2025

Across 30 payments — averaging $54.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$723
  • Bausch & Lomb Americas Inc.$354
  • NEW World Medical,inc.$255
  • Aerie Pharmaceuticals, Inc.$120
  • Rxsight Inc$105
  • Alcon Puerto Rico Inc$42
  • plus $46 from 2 others

What the payments were for

  • Food & beverage$1,646100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)18$723
Bausch & Lomb Americas Inc.4$354
NEW World Medical,inc.2$255
Aerie Pharmaceuticals, Inc.1$120
Rxsight Inc1$105
Alcon Puerto Rico Inc2$42
Mallinckrodt Hospital Products Inc.1$31
Alcon1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few glaucoma specialist providers in Puerto Ricoto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$15,990
Medicare patients
43
Services billed
193

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost1,122$297,060
Alphagan PBrimonidine Tartrate283$65,676
CombiganBrimonidine Tartrate/Timolol261$56,272
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol385$55,215
XiidraLifitegrast76$53,774
RestasisCyclosporine77$47,388
AzoptBrinzolamide79$29,239
Brimonidine Tartrate501$28,353
SimbrinzaBrinzolamide/Brimonidine Tart128$27,637
Latanoprost1,309$17,452
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat504$17,175
Prednisolone Acetate395$16,996
RhopressaNetarsudil Mesylate50$16,319
VyzultaLatanoprostene Bunod61$15,815
Fluorometholone232$15,674

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Alphagan P, Combigan, Restasis$723$466,3961,743 claims
Bausch & Lomb Americas Inc.Xiidra, Vyzulta$354$69,589137 claims
AlconAzopt, Simbrinza$16$56,875207 claims
Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan$120$27,18381 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few glaucoma specialist providers in Puerto Ricoon file to place this against a meaningful peer group, so we don't.

Other glaucoma specialist in San Juan

Where these figures come from

Is this you, or does something look wrong? →